Dermatology

Curevo Vaccine announces closing of $26m Series A1 round

Clinical-stage biotechnology company Curevo Vaccine has announced the closing of $26m Series A1 financing round.

Quoin Pharmaceuticals signs license, distribution agreement with WinHealth Pharma

Quoin Pharmaceuticals has signed a license and distribution agreement with Hong Kong WinHealth Pharma Group for its lead product candidate, QRX003 for Netherton Syndrome and a second pipeline product, QRX004 for Epidermolysis Bullosa.

Sanofi agrees to buy Austria-based Origimm Biotechnology

Sanofi has signed an agreement to buy Origimm Biotechnology, an Austria-based privately owned biotechnology company with focus on virulent skin microbiome components and antigens from bacteria causing skin disease.

AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis

AbbVie has submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) and SKYRIZI (risankizumab, 150 mg) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), respectively, for the treatment of adults with active psoriatic arthritis.